GlaxoSmithKline is to split its drug development teams into smaller and more focused groups paid by results, in a new shake-up to its approach to research and development.

Patrick Vallance, head of drug discovery, told a conference in London on Monday that GSK would increasingly try to become “more biotech-like” in its efforts to stimulate innovation.